|
|
|
|
|
by clnq
1275 days ago
|
|
I don't know how the economics can or would work out for a modern drug company. It's agreeable that Western personalized medicine seems to lag behind Europe and Asian countries like China. However, this Georgian phage producer does sell patentable boxed-up phages that consume common bacteria, like S. aureus, which has been discussed for its antibiotic resistance in academia a lot - https://phage.ge/products/pyo-bacteriophage/?lang=en. Years ago, I stumbled across some online stores that used to sell these products in Europe and the US, but now I can't find them. This makes me think that a traditional distribution model for these drugs can work. But there is too much medical skepticism for phage demand. And phages are often slower to work than antibiotics, so the latter option is more practical in treatment... when it works. |
|